Clinical trial
Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary…
NCT00006026 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00006026 |
|---|---|
| Title | Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract |
| Official title | Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Advanced/Metastatic Urothelial Tract Tumors |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer |
| Intervention type | Drug |
| Interventions | rubitecan |
| Enrollment | 21 |
| Start date | May 1, 2000 |
| Primary completion | Oct 1, 2001 |
| First posted | Mar 16, 2004 |
| Last update posted | Sep 24, 2012 |
| Countries | Belgium, France, Israel, Italy, Netherlands, Spain, Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: